×
About 2,338 results

ALLMedicine™ Chondrosarcoma Center

Research & Reviews  890 results

Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant ...
https://doi.org/10.1016/j.anndiagpath.2022.151967
Annals of Diagnostic Pathology; Thangaiah JJ, Westling BE et. al.

May 15th, 2022 - Loss-of-function mutations in EED and SUZ12, core components of the polycomb repressive complex 2 (PRC2), occur in >90% of sporadic and radiation-associated malignant peripheral nerve sheath tumors (MPNST) and in roughly 70% of NF1-related tumors....

Resection and reconstruction of huge tumors in the chest wall.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097317
Journal of Cardiothoracic Surgery; Dai Z, Maihemuti M et. al.

May 14th, 2022 - To evaluate the experience and effects of resection and reconstruction of 4 cases of huge tumors in the chest wall. The clinical data of 4 patients with huge tumors in the chest wall from July 2015 to January 2020 were collected and analyzed. Ther...

AG-120 in People With IDH1 Mutant Chondrosarcoma
https://clinicaltrials.gov/ct2/show/NCT04278781

May 6th, 2022 - This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.

LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant ch...
https://doi.org/10.1007/s11060-022-04012-9 10.1023/A:1008947301735 10.1002/hed.23415 10.2106/00004623-198163030-00035 10.1016/j.amjoto.2013.12.018 10.1016/S1470-2045(11)70337-0 10.1016/j.wneu.2021.09.027 10.1002/cncr.28032 10.1016/j.wneu.2017.06.106 10.18632/oncotarget.3083 10.1016/j.yexcr.2005.12.016 10.1016/j.yexmp.2015.11.031 10.3892/or.2012.2199 10.1136/gut.2009.202739 10.1016/j.canlet.2016.01.008 10.1016/j.yexcr.2005.12.016 10.1038/sj.bjc.6603545 10.3892/ijo.2015.2923 10.1016/j.ejca.2012.09.032 10.1158/0008-5472.CAN-14-2040 10.1007/s00432-014-1759-3 10.3389/fonc.2018.00391 10.1186/1476-4598-7-31 10.1387/ijdb.072435nh 10.1006/geno.1995.1163 10.3892/ijo.2014.2268 10.1038/modpathol.2008.144 10.1371/journal.pone.0083187 10.4103/sni.sni_399_16 10.1242/jcs.00174 10.1007/BF03401929 10.1371/journal.pone.0035340 10.1016/j.febslet.2006.04.082 10.1186/1471-2407-7-198 10.1016/j.urolonc.2012.02.002 10.1158/0008-5472.CAN-10-0592 10.1038/onc.2012.216 10.1038/nrm1499 10.1021/bi961149j 10.1038/onc.2015.166 10.2174/15680096113136660102 10.4161/cam.4.2.10943 10.5858/arpa.2020-0258-RA
Journal of Neuro-oncology; Vanderheijden C, Vaessen T et. al.

May 5th, 2022 - Chordomas are malignant tumors that develop along the neuraxis between skull-base and sacrum. Chondrosarcomas show similarities with chordomas, yet show less malignant behavior. LIM and SH3 protein 1 (LASP1) is a cytoskeletal protein known to prom...

Mutation of KIT in cellular extraskeletal myxoid chondrosarcoma: a case report and lite...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052449
Diagnostic Pathology; Wang C, You ZJ et. al.

Apr 30th, 2022 - Extraskeletal myxoid chondrosarcomas (EMCs) are solid tumors that have been genetically and biologically characterized. Only a few studies have discussed the role of the KIT gene or CD117 expression in EMCs, identified by immunohistochemical (IHC)...

see more →

Clinicaltrials.gov  18 results

AG-120 in People With IDH1 Mutant Chondrosarcoma
https://clinicaltrials.gov/ct2/show/NCT04278781

May 6th, 2022 - This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
https://clinicaltrials.gov/ct2/show/NCT04521686

Apr 28th, 2022 - This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with IDH1 R132-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, ...

Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
https://clinicaltrials.gov/ct2/show/NCT02821507

Apr 20th, 2022 - Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease the outcome is po...

A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
https://clinicaltrials.gov/ct2/show/NCT02389244

Apr 4th, 2022 - METHODOLOGY: Randomized, placebo-controlled, multicentric, phase II study -This is a double-blind placebo-controlled trial, with 5 cohorts: cohort A: Osteosarcoma, cohort B: Ewing sarcoma, cohort C: Chondrosarcoma, cohort D : chondroma, cohort E: ...

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma
https://clinicaltrials.gov/ct2/show/NCT05193188

Jan 14th, 2022 - We intend to explore the response of chondrosarcoma to PD-1 monoclonal antibody and the influence of different IDH genotypes on PD-1 monoclonal antibody response. Patients with unresectable locally advanced or metastatic chondrosarcomas(CS), inclu...

see more →

News  18 results

Key Advances in Sarcoma Lead to More Personalized Medicine Efforts
https://www.onclive.com/view/key-advances-in-sarcoma-lead-to-more-personalized-medicine-efforts

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...

Randall Reviews Rare Incidence of and Challenges With Spinal Sarcomas
https://www.onclive.com/view/randall-reviews-rare-incidence-of-and-challenges-with-spinal-sarcomas

Oct 6th, 2021 - Sarcoma of mobile vertebral column continues to be a rare finding in patients, but is one with poor survival outcomes and varying prognostic factors, explained R. Lor Randall, MD. Because primary sarcomas that originate in the spine are so rare, ...

Bioengineered Models Could Improve Understanding of Bone Cancer, Metastases
https://www.onclive.com/view/bioengineered-models-could-improve-understanding-of-bone-cancer-metastases

Oct 6th, 2021 - Tissue-engineered platforms could pave the way for a deeper understanding of cancer arising in or metastasizing to the bone and ultimately lead to targeted therapeutic developments, according to a review published in the Journal of Biomechanics. ...

Trastuzumab Deruxtecan Shows Promise Beyond Breast and Gastric Tumors
https://www.onclive.com/view/trastuzumab-deruxtecan-shows-promise-beyond-breast-and-gastric-tumors

Oct 6th, 2021 - Bob T. Li, MD, MPH Fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201), a HER2-directed antibody¬—drug conjugate (ADC), demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types, according to findings ...

Chemotherapy Sensitivity in Soft Tissue Sarcoma
https://www.onclive.com/view/chemotherapy-sensitivity-in-soft-tissue-sarcoma

Apr 2nd, 2021 - Transcript:William D. Tap, MD: One of the things I want to get back to is this comment that sarcoma is a chemotherapy-insensitive disease. I’m sure we can talk about, and we will, some diseases that are chemotherapy-insensitive. But what’s your th...

see more →

Patient Education  9 results see all →